Assessment of vaccine potential of the Neisseria-specific protein NMB0938

Vaccine

Volumn 27, Issue 49, 2009, Pages 6910-6917

  Sardiñas, Gretel ^a   Climent, Yanet ^a,b   Rodríguez, Yaindrys ^a   González, Sonia ^a   García, Darién ^a   Cobas, Karem ^a   Caballero, Evelin ^a   Pérez, Yusleydis ^a   Brookes, Charlotte ^c   Taylor, Stephen ^c   Gorringe, Andrew ^c   Delgado, Maité ^a   Pajón, Rolando ^a   Yero, Daniel ^a,b  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b FINLAY INSTITUTE   (Cuba)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Meningococcus serogroup B; Sequence variability; Surface antigen

Indexed keywords

ALUMINUM HYDROXIDE; ANTISERUM; BACTERIAL DNA; BACTERIAL POLYSACCHARIDE; COMPLEMENT COMPONENT C3B; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; RECOMBINANT LIPOPROTEIN NMB0938; RECOMBINANT LIPOPROTEIN NMB0938 ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE CLUSTER; GENE EXPRESSION; GENETIC VARIABILITY; IMMUNOGENICITY; MENINGOCOCCOSIS; MOUSE; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VACCINE PRODUCTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOTTING, WESTERN; COMPLEMENT SYSTEM PROTEINS; COMPUTATIONAL BIOLOGY; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS, SEROGROUP B; PHYLOGENY; RATS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT;

EID: 70350749405     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.005     Document Type: Article

References (61)

1. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 Suppl. 12 (2004) S274-S279
2. Stephens D.S., Greenwood B., and Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369 9580 (2007) 2196-2210
3. Finne J., Bitter-Suermann D., Goridis C., and Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138 12 (1987) 4402-4407
4. Hayrinen J., Jennings H., Raff H.V., Rougon G., Hanai N., Gerardy-Schahn R., et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 171 6 (1995) 1481-1490
5. Morley S.L., and Pollard A.J. Vaccine prevention of meningococcal disease, coming soon?. Vaccine 20 5-6 (2001) 666-687
6. Sacchi C.T., Whitney A.M., Popovic T., Beall D.S., Reeves M.W., Plikaytis B.D., et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States. 1992-1998. J Infect Dis 182 4 (2000) 1169-1176
7. Tondella M.L., Popovic T., Rosenstein N.E., Lake D.B., Carlone G.M., Mayer L.W., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 38 9 (2000) 3323-3328
8. Poolman J.T. Development of a meningococcal vaccine. Infect Agents Dis 4 1 (1995) 13-28
9. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63 12 (1995) 4642-4652
10. Perrett K.P., and Pollard A.J. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5 12 (2005) 1611-1625
11. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
12. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72 4 (2004) 2088-2100
13. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
14. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
15. Nissen M.D., Marshall H., Richmond P., Lambert S.B., Roberton D., and Gruber W.C. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine. Proceedings of the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases-ESPID (2008)
16. García D., Cobas K., Sardiñas G., Delgado M., Climent Y., Yero D., et al. Neisseria meningitidis genome identification of new potential vaccine antigens. Proceedings of the 16th International Pathogenic Neisseria Conference. Rotterdam, The Netherlands (2008)
17. Yero D., Pajon R., Niebla O., Sardiñas G., Vivar I., Perera Y., et al. Bicistronic expression plasmid for the rapid production of recombinant fused proteins in Escherichia coli. Biotechnol Appl Biochem 44 Pt 1 (2006) 27-34
18. Vaughan T.E., Skipp P.J., O'Connor C.D., Hudson M.J., Vipond R., Elmore M.J., et al. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine 24 25 (2006) 5277-5293
19. Peng J., Yang L., Yang F., Yang J., Yan Y., Nie H., et al. Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. Genomics 91 1 (2008) 78-87
20. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., et al. Clustal W and Clustal X version 2.0. Bioinformatics 23 21 (2007) 2947-2948
21. Kumar S., Tamura K., and Nei M. MEGA3: integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5 2 (2004) 150-163
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 259 (1970) 680-685
23. Delgado M., Yero D., Niebla O., Gonzalez S., Climent Y., Perez Y., et al. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate. Vaccine 25 50 (2007) 8420-8431
24. Rosenqvist E., Wedege E., Hoiby E.A., and Froholm L.O. Serogroup determination of Neisseria meningitidis by whole-cell ELISA, dot-blotting and agglutination. APMIS 98 6 (1990) 501-506
25. Wedege E., and Froholm L.O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51 2 (1986) 571-578
26. Findlow J., Taylor S., Aase A., Horton R., Heyderman R., Southern J., et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun 74 8 (2006) 4557-4565
27. Yero C.D., Pajon F.R., Caballero M.E., Cobas A.K., Lopez H.Y., Farinas M.M., et al. Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model. Vaccine 23 7 (2005) 932-939
28. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95 6 (1998) 3140-3145
29. Pollard A.J., and Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 19 4 (2000) 333-344
30. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
31. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19 17-19 (2001) 2688-2691
32. Keenan J., Oliaro J., Domigan N., Potter H., Aitken G., Allardyce R., et al. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun 68 6 (2000) 3337-3343
33. Sigal L.H., Zahradnik J.M., Lavin P., Patella S.J., Bryant G., Haselby R., et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein A Lyme disease vaccine study consortium. N Engl J Med 339 4 (1998) 216-222
34. Hanson M.S., Cassatt D.R., Guo B.P., Patel N.K., McCarthy M.P., Dorward D.W., et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun 66 5 (1998) 2143-2153
35. Murphy T.F., Kirkham C., and Lesse A.J. Construction of a mutant and characterization of the role of the vaccine antigen P6 in outer membrane integrity of nontypeable Haemophilus influenzae. Infect Immun 74 9 (2006) 5169-5176
36. Cannon J.G. Conserved lipoproteins of pathogenic Neisseria species bearing the H.8 epitope: lipid-modified azurin and H. 8 outer membrane protein. Clin Microbiol Rev Suppl 2 (1989) S1-S4
37. Rokbi B., Mignon M., Maitre-Wilmotte G., Lissolo L., Danve B., Caugant D.A., et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun 65 1 (1997) 55-63
38. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 5459 (2000) 1809-1815
39. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 11 (2003) 1730-1740
40. Hsu C.A., Lin W.R., Li J.C., Liu Y.L., Tseng Y.T., Chang C.M., et al. Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential. Proteomics 8 10 (2008) 2115-2125
41. Kizil G., Todd I., Atta M., Borriello S.P., Ait-Tahar K., and Ala'Aldeen D.A. Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen. Infect Immun 67 7 (1999) 3533-3541
42. Yang Q.L., Tinsley C.R., and Gotschlich E.C. Novel lipoprotein expressed by Neisseria meningitidis but not by Neisseria gonorrhoeae. Infect Immun 63 5 (1995) 1631-1636
43. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 25-26 (2001) 3331-3346
44. Siegrist C.A. Vaccination in the neonatal period and early infancy. Int Rev Immunol 19 2-3 (2000) 195-219
45. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22 27-28 (2004) 3658-3668
46. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
47. Richmond P., Borrow R., Miller E., Clark S., Sadler F., Fox A., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179 6 (1999) 1569-1572
48. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24 24 (2006) 5093-5107
49. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., and Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 8 3 (2001) 616-623
50. Zollinger W.D., and Mandrell R.E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 40 1 (1983) 257-264
51. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 1 (2006) 501-510
52. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176 12 (2006) 7566-7575
53. Granoff D.M., Welsch J.A., and Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77 2 (2009) 764-769
54. Gorringe A.R., Reddin K.M., Funnell S.G., Johansson L., Rytkonen A., and Jonsson A.B. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 23 17-18 (2005) 2214-2217
55. Saukkonen K., Leinonen M., Abdillahi H., and Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7 4 (1989) 325-328
56. Toropainen M., and Saarinen L. Van Der LP, Kuipers B, Kayhty H. Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model. Microb Pathog 30 3 (2001) 139-148
57. Toropainen M., Kayhty H., Saarinen L., Rosenqvist E., Hoiby E.A., Wedege E., et al. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 17 20-21 (1999) 2677-2689
58. Hou V.C., Koeberling O., Welsch J.A., and Granoff D.M. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192 4 (2005) 580-590
59. Balmer P., and Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 3 1 (2004) 77-87
60. Sardiñas G., Yero D., Climent Y., Caballero E., Cobas K., and Niebla O. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J Med Microbiol 58 Pt 2 (2009) 196-208
61. Arenas J., Abel A., Sanchez S., Marzoa J., Berron S., Van Der L.P., et al. A cross-reactive neisserial antigen encoded by the NMB0035 locus shows high sequence conservation but variable surface accessibility. J Med Microbiol 57 Pt 1 (2008) 80-87